USD 4.30 billion
Meningococcal Vaccines Market Size, Share, Growth Analysis, By Vaccine Type (Polysaccharide Vaccines, Conjugate Vaccines), By Brand (Menactra, Menveo), By Age Group (Infants, Children), By End User (Hospitals, Clinics), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2154 |
Region:
Global |
Published Date: December, 2024
Pages:
219
|Tables:
59
|Figures:
75
Meningococcal Vaccines Market Insights
Meningococcal Vaccines Market size was valued at USD 3.5 Billion in 2023 and is poised to grow from USD 3.71 Billion in 2024 to USD 5.96 Billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).
The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), there are an estimated 1.2 million cases of bacterial meningitis worldwide. Furthermore, increasing immunization programs, growing awareness about the disease, and increasing R&D activities related to meningococcal vaccines will drive the meningococcal vaccines market growth during the forecast period.
Campaigns and awareness programs are run by government & non-government organizations, such as the National Meningitis Association (NMA), the Meningitis Research Foundation of Canada, the Meningitis B Action Project, and others. These organizations help to promote ongoing research and new prevention strategies. Thus, these factors are expected to fuel the growth of the meningococcal vaccines industry in the coming years.
The meningococcal vaccine is designed to protect against Neisseria meningitidis infection. Vaccines targeting several strains of meningococcus including A, B, C, W-135 and Y are available. Vaccines can be monovalent, targeting a specific meningococcus, or multivalent in nature. The major factors driving the rise of the global meningococcal vaccines market are increasing availability and popularity of travel vaccine, advancement in R&D related to vaccine technology. Their increased inclusion in national immunization programs is expected to contribute to the growth of the market. Stringent regulatory guidelines are expected to hamper market growth.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Conjugate vaccines
Fastest Growth
Polysaccharide vaccines
Growth Rate
6.5% CAGR
Global Meningococcal Vaccines Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Meningococcal Vaccines Market Segmental Analysis
Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Sales Channel
The public segment accounted for the largest market share of 69.4% in 2023 and is expected to remain dominant throughout the forecast period. For example, in July 2020, the government of New South Wales changed the immunization schedule, and the government is funding Bexsero for Aboriginal children & some at-risk people and Nimenrix for people at high risk of infection. Public sector plays an important role in the meningococcal vaccines market by driving mass immunization programs, funding vaccine development, ensuring equal access. Governments and international health organizations, such as the World Health Organization (WHO) and Gavi, play a central role in funding vaccination campaigns, especially in regions with high disease prevalence like sub-Saharan Africa's "meningitis belt."
The private segment is primarily driven by the growing demand for meningococcal vaccines in developing countries. Moreover, increasing disposable income, increasing outbound traveling from work, study, pilgrims for Mecca and Umrah, and increasing awareness is driving the demand for vaccination against meningococcal vaccines through private sales channels. The private segment makes a significant contribution by promoting innovation, developing vaccines and improving the global distribution network. Pharmaceutical companies such as Pfizer, Sanofi and GlaxoSmithKline (GSK) are investing heavily in R&D to develop advanced drugs with broader vaccine coverage and longer immunity. Private sectors have also contributed to products a production has increased to meet the growing demand for meningococcal vaccines in developed and emerging markets.
Analysis by End-User
As per meningococcal vaccines market analysis, the children & adults segment accounted for a significant market share of 78.9% in 2023 due to initiatives undertaken by healthcare organizations to vaccinate the adult population and ongoing clinical trials to develop novel vaccines for teenagers. The segment plays an important role in driving the meningococcal vaccines market, mainly because of its inclusion in routine vaccination programs and campaigns protect against high-risk. Adolescents are particularly targeted for protection because they are likely to be asymptomatic, facilitating disease transmission MenACWY (Four-link explanation) etc. Vaccines are generally administered to this group, especially before travel to endemic regions or during outbreaks.
The infants segment is expected to be the fastest growing segment during the forecast period owing to rising depression. According to the European Center for Disease Control and Prevention (ECDC) in 2017, IMD incidence was observed to be the highest in infants. In Europe, the prevalence was found to be 8.2 confirmed cases per 100,000 children of age under 1 year. Furthermore, increasing research on available vaccines to determine their impact in preventing the target disease is anticipated to boost market growth. The infants segment is another important segment of the market, mainly due to its susceptibility to severe sequelae from meningococcal infection, which causes the highest incidence of meningitis and sepsis in infants and requires vaccination.
Global Meningococcal Vaccines Market Size By Type
To get detailed analysis on other segments, Request For Free Sample Report
Meningococcal Vaccines Market Regional Insights
As per meningococcal vaccines market outlook, North America dominated the overall market in terms of revenue in 2023 with a 57.0% share. Positive suggestions & support from governments and high R&D investme5nts are some of the factors driving the North America region. Furthermore, improved healthcare infrastructure and awareness campaigns within the sector are expected to propel market growth. Marketers are also actively involved in awareness campaigns to increase uptake of meningococcal vaccine in the region. For example, in August 2021, GSK plc. launched the ASK2BSure campaign to encourage parents to visit doctors for meningitis B vaccination for their children.
The Asia Pacific region in the market is anticipated to grow significantly during the forecast period. This is due to the high incidence of meningococcal virus transmission leading to a significant increase in the number of clinical programs for effective meningococcal vaccines. The increasing number of children, increasing government initiatives to combat the spread of the disease contribute to the growth of meningococcal vaccines in this region. Moreover, non-profit organizations provide information to people and health professionals. Thus, the intake of antimeningococcal drugs is expected to increase.
Global Meningococcal Vaccines Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Meningococcal Vaccines Market Dynamics
Meningococcal Vaccines Market Drivers
Increased Incidence of Meningococcal Diseases
- One of the major drivers for the meningococcal vaccines market is the rising incidence of meningococcal diseases across the globe. Meningitis and septicemia due to Neisseria meningitis have high mortality and severe long-term effects, such as neurological damage, which leads health care providers to prioritize prevention through vaccination. Regions, especially Africa Sub-Saharan Africa, known as the "meningitis belts," reports widespread infection.
Increased Awareness and Vaccination Programs
- Increased awareness of the risk of meningococcal disease and the availability of vaccines has expanded vaccination programs worldwide. Governments and health organizations are conducting campaigns to promote routine vaccination for children, teenagers, and high-risk groups, such as individuals with compromised immunity or travelers to endemic regions. The creation of the enlarged organization (WHO) increased the market demand for vaccines.
Meningococcal Vaccines Market Restraints
High Cost of Vaccines
- One of the major challenges in the meningococcal vaccines market is the high cost associated with manufacturing and distribution. Advanced vaccines, especially those using conjugated recombinant technologies, are not widely available in low-income areas where the disease burden is often high. Even with government and non-governmental subsidies, affordability remains a key concern that hampers widespread immunization efforts.
Limited Vaccine Coverage in Low-income Areas
- Despite increasing awareness and international efforts, vaccination in low-income settings remains a challenge. Large sections of the population are still not vaccinated due to issues such as inadequate health care, resource barriers and insufficient funds for vaccines. These gaps expose vulnerable populations to the risk of outbreaks, underscoring the need for sustained investments and strategic partnerships to improve vaccine access.
Request Free Customization of this report to help us to meet your business objectives.
Meningococcal Vaccines Market Competitive Landscape
The meningococcal vaccines market is highly competitive, with leading players focusing on innovation, strategic partnerships and market expansion to maintain their leadership. Leading companies engaged in research and development (R&D) to create vaccines extensive. For example, Serum has partnered with PATH-WHO to increase access to meningitis vaccines in Africa.
Meningococcal Vaccines Market Top Player’s Company Profiles
- Pfizer Inc.
- GlaxoSmithKline plc
- Sanofi S.A.
- Merck & Co., Inc.
- Novartis AG
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- Biomed Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Hualan Biological Engineering Inc.
- Walvax Biotechnology Co., Ltd.
- Chongqing Zhifei Biological Products Co., Ltd.
- Emergent BioSolutions Inc.
- Incepta Vaccine Ltd.
- Panacea Biotec Ltd.
- LG Chem Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Valneva SE
- Vaxart, Inc.
Meningococcal Vaccines Market Recent
- In March 2023, GSK plc achieved positive results for the MenABCWY combination vaccine candidate in a pivotal phase 3 clinical trial. In individuals aged 10-25 years, the vaccine will be administered as two doses.
- In September 2022, Janssen Pharmaceuticals received FDA approval for its Meniquadfi meningococcal vaccine, which protects against four meningococcal disease serogroups.
- In May 2021, Bio-Manguinhos and Emergex (UK) signed the agreement. The agreement establishes a framework for future clinical trials, meningococcal vaccine development, COVID-19 vaccine development, sales and marketing and distribution within the Brazilian Ministry of National Health.
Meningococcal Vaccines Key Market Trends
- Shift Toward Combination Vaccines: A notable meningococcal vaccines market trend is the increasing acceptance of combination vaccines that protect against multiple meningococcal strains. The demand for quadrivalent vaccines targeting serogroups A, C, W, and Y is increasingly preferred due to their broader coverage and reduced need for multiple doses. This shift addresses logistical challenges and improves immunization adherence, enhancing overall healthcare outcomes.
- Advancements in Vaccine Development Technologies: Biotechnological innovations are changing the development of meningococcal vaccines. Recombinant DNA technology and conjugate vaccines are becoming increasingly popular due to their ability to induce long-lasting immunity with few side effects. Research is also underway to develop vaccines for serogroup B, which historically has been challenging to target. These developments are expected to open new avenues for market expansion.
Meningococcal Vaccines Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, the meningococcal vaccines market is experiencing strong growth, driven by rising incidence of meningococcal diseases and increasing global vaccination efforts. The demand has emerged, as government policies and outreach campaigns expand vaccine coverage. The advances in biotechnology, such as recombinant DNA and conjugate vaccine technology, are paving the way for next-generation vaccines with broad safety and durable immunity. But the market faces challenges, including high production costs and limited availability in low-income areas, where the burden of disease is most severe. Vaccines an adoption of combinations and innovations targeting previously difficult-to-manage serogroups are shaping key market trends. Through continued investment and global cooperation, the market holds the promise of reducing meningococcal diseases worldwide.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 4.30 billion |
| Market size value in 2031 | USD 7.58 billion |
| Growth Rate | 6.5% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
Meningococcal Vaccines Market Recent
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Meningococcal Vaccines Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Meningococcal Vaccines Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Meningococcal Vaccines Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Meningococcal Vaccines Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Meningococcal Vaccines Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Meningococcal Vaccines Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
